U.S. pharma large copyright scrapped two experimental weight loss drugs final yr—a the moment-every day tablet, lotiglipron, on account of elevated liver enzymes in addition to a twice-day-to-day pill, danuglipron, on account of solid Unintended effects—but CEO Albert Bourla has mentioned the company is decided to “play and win” in the bein